PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31930374-2	2020	In vitro and in vivo studies have reported that ambroxol increases beta-glucocerebrosidase (GCase) enzyme activity and reduces alpha-synuclein levels.	Ambroxol	48-56	synuclein alpha	Homo sapiens	127-142	
35179198-0	2022	Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model.	Ambroxol	0-8	synuclein alpha	Homo sapiens	26-41	
35179198-10	2022	Ambroxol significantly enhanced GCase activity and decreased both tau and alpha-synuclein levels in cholinergic neurons.	Ambroxol	0-8	synuclein alpha	Homo sapiens	74-89	
31930374-19	2020	Conclusions and Relevance: The study results suggest that ambroxol therapy was safe and well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF alpha-synuclein levels were increased.	Ambroxol	58-66	synuclein alpha	Homo sapiens	177-192	
28741230-6	2017	Disease-modifying approaches are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins, including immunotherapy targeting alpha-synuclein and an ongoing trial using ambroxol which increases glucocerebrosidase activity to lower the levels of the protein alpha-synuclein.	Ambroxol	224-232	synuclein alpha	Homo sapiens	312-327	
27859541-9	2016	RESULTS: Ambroxol treatment resulted in increased brain glucocerebrosidase activity in (1) wild-type mice, (2) transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and (3) transgenic mice overexpressing human alpha-synuclein.	Ambroxol	9-17	synuclein alpha	Homo sapiens	256-271	
27859541-10	2016	Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels.	Ambroxol	63-71	synuclein alpha	Homo sapiens	46-61	
27859541-10	2016	Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels.	Ambroxol	63-71	synuclein alpha	Homo sapiens	97-112	
27859541-10	2016	Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels.	Ambroxol	63-71	synuclein alpha	Homo sapiens	97-112	
27859541-11	2016	INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels.	Ambroxol	55-63	synuclein alpha	Homo sapiens	264-279	
27859541-11	2016	INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels.	Ambroxol	55-63	synuclein alpha	Homo sapiens	299-314